100% Tariffs on Imported Drugs: What the New Pharma Order Means
On Wednesday, the White House signed an executive order imposing up to 100% tariffs on patented pharmaceutical imports, the most aggressive trade action ever taken against the global drug supply chain. The announcement landed on the one-year anniversary of “Liberation Day,” and the details matter more than the headline.
The executive order, signed April 2, invokes Section 232 of the Trade Expansion Act, the same national security authority used for steel and aluminum levies. The top-line rate of 100% applies to patented drugs and their active pharmaceutical ingredients. But the order is built around exemptions, and the exemptions tell you more about the policy’s true aim than the headline rate does.
Who Actually Pays 100%?
Not many companies, at least not right away. The 100% rate kicks in after 120 days for large drugmakers and 180 days for smaller firms that rely on contract manufacturers. That delay is deliberate. The administration is using the threat of the tariff to force companies to the negotiating table, not to collect revenue on day one.
Companies that have already signed Most Favored Nation pricing agreements with the Department of Health and Human Services and onshoring commitments with the Department of Commerce pay 0% through January 20, 2029. The White House lists 13 companies that have reached such deals. Companies that commit to moving production to the U.S. but have not yet completed pricing agreements face a 20% tariff, rising to 100% after four years if they fail to follow through.
Drugs imported from countries with broader trade agreements get their own rates. The European Union, Japan, South Korea, and Switzerland face a 15% tariff. The United Kingdom pays 10% under the terms of a recently concluded bilateral pharmaceutical agreement.
What Is Exempt?
The carve-outs are significant. Generic drugs, biosimilars, and their associated active ingredients are excluded entirely, at least for now. The administration said it would reassess that exemption in one year. Orphan drugs, animal health products, and certain specialty pharmaceuticals tied to urgent public health needs are also exempt if they originate in countries with existing trade deals.
That means the order primarily targets branded, patent-protected drugs manufactured overseas by companies that have not agreed to lower their U.S. prices or bring production stateside.
Why This Matters for Investors
The policy creates a two-track pharmaceutical market. Companies that negotiate early get favorable terms and regulatory certainty through at least 2029. Companies that resist face a tariff wall that could make their imported products uncompetitive.
For healthcare stocks broadly, the near-term impact is muted because so many companies are already exempt or in active negotiations. The bigger risk sits with mid-cap biotech firms that manufacture overseas and lack the scale to relocate production quickly. Building a pharmaceutical manufacturing facility in the U.S. takes three to five years and costs hundreds of millions of dollars.
The generic drug exemption is the most important detail for consumers. Roughly 90% of prescriptions filled in the United States are generic drugs, and a large share of those are manufactured in India and China. Applying tariffs to generics could have triggered immediate price increases at pharmacies nationwide. The administration chose not to go there, at least for now.
The Broader Tariff Context
This order arrived on the one-year anniversary of Liberation Day, and it was paired with a restructuring of metals tariffs. Articles made entirely or almost entirely of aluminum, steel, or copper now face a flat 50% tariff on their full value, while derivative articles pay 25%. Products containing 15% or less metal content are no longer subject to Section 232 levies.
The pharmaceutical and metals orders together signal a shift in tariff strategy: fewer blanket rates, more targeted leverage designed to force specific corporate behavior.
What Comes Next
Markets were closed Friday for Good Friday and will reopen Monday, April 6. Investors will get their first chance to react to both the pharma tariffs and Friday morning’s stronger-than-expected March jobs report, which showed 178,000 new jobs against a consensus forecast of 65,000. The combination of aggressive trade policy and resilient employment data gives the market conflicting signals to digest over the long Easter weekend.
The 120-day clock for large drugmakers starts ticking now. Watch for announcements from companies that have not yet signed pricing or onshoring agreements. Those that move first will likely see their stocks stabilize. Those that wait may find themselves priced out of the U.S. market.
Ferrante Capital LLC is a registered investment adviser. This content is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Forward-looking statements reflect our views as of the publication date and are subject to change. Ferrante Capital and its principals may hold positions in securities discussed in this article. Past performance is not indicative of future results. Please consult a qualified financial professional before making investment decisions.